Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AIDS BILL WITH TREATMENT IND PROVISIONS AND FDA COMMISSIONER CONFIRMATION BILL PASS HOUSE AND SENATE OCT. 13 IN OMNIBUS HEALTH PROGRAM LEGISLATION

Executive Summary

The FDA commissioner confirmation bill cleared both the House and Senate along with an AIDS bill on Oct. 13 in a health legislation conglomerate entitled the "Health Omnibus Programs Extension of 1988." Compiled by the Senate the day it was passed, the bill (S 2889) also contains a provision for state-administered reimbursement assistance for outpatient immunosuppressive drugs. Title II of the legislation contains Waxman's AIDS bill (HR 5142), which directs the Department of Health and Human Services to encourage Treatment INDs for AIDS therapies through public notices of the potential usefulness of experimental drugs in AIDS patients ("The Pink Sheet" Sept. 26, p. 11). The publicity aspect of the Waxman proposal relates to one of the demands of the AIDS activist group. In general, Title II provides for new AIDS research and training programs and establishes a state block grant program to provide home health services for AIDS patients. The section contains an authorization for federal research grants of $ 40 mil. for fiscal 1989 and "such sums as may be necessary for each of the fiscal years 1990 and 1991." The legislation also requests a report from HHS on the possible advantages of establishing a consortia among businesses and nonprofit research institutions for the development of AIDS drugs and vaccines. Title II establishes two-year formula grants for state assistance to AIDS patients for home and community-based health services including outpatient I.V. drugs, routine diagnostic tests administered at home and durable medical equipment. The amount allotted to states would be determined by a formula. Appropriations for the assistance fund is $ 100 mil. for each of the fiscal years 1989 and 1990. Under Title IV of the legislation, which contains the Organ Transplant Amendments of 1988, a two-year block grant is provided for outpatient immunosuppressive drug therapy. The bill authorizes $ 5 mil. for each of the fiscal years 1988 through 1990 for state-administered assistance for organ transplant patients who are not eligible for reimbursement under Medicare, Medicaid or private insurance. Senate confirmation of the FDA commissioner is contained in Title V of S 2889. The FDA commissioner bill passed the House in July after the Senate had adopted it in February. Sen. Gore (D-Tenn.) and Rep. Waxman were the chief sponsors of the bill. Title V specifies that future FDA commissioners "shall be appointed by the President with the advice and consent of the Senate." While passage of the bill may increase the political pressure on future FDA commissioners, it could increase Com. Young's prospects for staying on if a Bush Administration is formed. As current commissioner, Young may be able to continue without facing confirmation in a Democratic Congress. It he had to face confirmation, he would do so as a known figure.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel